Resistance to Imatinib in Patients with Chronic Myelogenous Leukemia and the Splice Variant BCR-ABL1(35INS)

PURPOSE: In patients with chronic myelogenous leukemia (CML), point mutations in the BCR-ABL1 kinase domain are the most common cause of treatment failure with a tyrosine kinase inhibitor (TKI). It is not clear whether the splice variant BCR-ABL1(35INS) is also associated with treatment failure. PAT...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Leuk Res
Egile Nagusiak: Berman, Ellin, Jhanwar, Suresh, Hedvat, Cyrus, Arcila, Maria E., Wahab, Omar Abdel-, Levine, Ross, Maloy, Molly, Ma, Wanlong, Albitar, Maher
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2016
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5625826/
https://ncbi.nlm.nih.gov/pubmed/27658269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2016.08.006
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak